Results 21 to 30 of about 694 (158)

Bilastine

Indian Journal of Drugs in Dermatology, 2018
Bilastine is a new second generation H1-antihistamine approved for the symptomatic treatment of allergic rhinitis (AR) and chronic urticaria (CU) in patients older than 12 years of age. AR and urticaria are very common clinical conditions that represent one of the most frequent reasons for a patient to visit their general ...
Jeet Gandhi, Kiran Godse, Gauri Godse
  +4 more sources

Comparative clinical assessment of updosing of bilastine and combination of levocetirizine and hydroxyzine in chronic spontaneous urticaria

Clinical Dermatology Review, 2022
Background: Second-generation antihistamines (SGAHs) are first-line drugs in management of chronic spontaneous urticaria (CSU). However, almost 50% of the patients do not respond to standard dose of SGAH.
Bela Shah, Deval Mistry, Neha Jangid, Shikha Shah, Shruti Kamat, Dhiraj Dhoot, Gaurav Deshmukh   +6 more
doaj   +1 more source

Comparison of Allergic Rhinitis Treatments on Patient Satisfaction: A MASK-air and EAACI Methodological Committee Report. [PDF]

Allergy
This study compares different medications for allergic rhinitis on patients' satisfaction and co‐medication use frequency. mHealth data suggest that intranasal corticosteroids (INCS) and fixed combinations of intranasal antihistamines (INAH) and corticosteroids are associated with higher treatment satisfaction than oral antihistamines (OAH).
Sousa-Pinto B, Vieira RJ, Bognanni A, Martini M, Ordak M, Paoletti G, Gil-Mata S, Amaral R, Bedbrook A, Bonadonna P, Brussino L, Canonica GW, Coutinho-Almeida J, Cruz ÁA, Czarlewski W, Dykewicz M, Giovannini M, Gemicioglu B, Ivancevich JC, Klimek L, Kvedariene V, Larenas-Linnemann DE, Marques-Cruz M, Moreira A, Niedoszytko M, Pereira AM, Papadopoulos NG, Pham-Thi N, Regateiro FS, Toppila-Salmi SK, Samolinski B, Sastre J, Taborda-Barata L, Thomander T, Koyuncu IV, Valiulis A, Vecillas LL, Ventura MT, Walusiak-Skorupa J, Xiang YK, Pfaar O, Fonseca JA, Zuberbier T, Schünemann HJ, di Bona D, Bousquet J.   +45 more
europepmc   +2 more sources

Bilastine in Refractory Chronic Spontaneous Urticaria: Disease Control and Cytokine Modulation in an Open-label Prospective Study

Indian Journal of Dermatology
Introduction: The treatment options for chronic spontaneous urticaria (CSU) primarily include second generation non-sedative antihistamine (SGAHs). Bilastine is a newer, nonsedating SGAH approved for urticaria in February 2019 by the Drugs Controller ...
Abhishek De, Sushil Singh, Disha Chakraborty, Aarti Sarda, Kiran Godse   +4 more
doaj   +2 more sources

Design, Optimization and Characterization of Self-Nanoemulsifying Drug Delivery Systems of Bilastine

Iraqi Journal of Pharmaceutical Sciences, 2023
          Self-nanoemulsifying drug delivery systems are innovative methods that have the potential to resolve a variety of drug formulation issues, including solubility, stability and bioavailability.
Ishraq Kadhim Abbas, Shaimaa Nazar Abd-AlHammid   +1 more
doaj   +1 more source

Efficacy of Oral Bilastine in Comparison to Levocetirizine in Allergic RhinitisA Randomised Clinical Study [PDF]

Journal of Clinical and Diagnostic Research, 2021
Introduction: Allergic rhinitis is a heterogeneous disorder characterised by major symptoms like sneezing, itching, nasal congestion and rhinorrhea.
M VANITHA, K SOWMINI, K SANTHA SHEELA KUMARI, Resu Neha Reddy   +3 more
doaj   +1 more source

Allergic Rhinitis and Its Impact on Asthma (ARIA)-EAACI Guidelines-2024-2025 Revision: Part II-Guidelines on Oral and Ocular Treatments. [PDF]

Allergy
ABSTRACT Background Oral and ocular medications are frequently used in the treatment of allergic rhinitis (AR). As part of the update of the Allergic Rhinitis and its Impact on Asthma (ARIA)‐EAACI guidelines, this manuscript presents the ARIA‐EAACI 2024–2025 recommendations for oral and ocular treatments.
Vieira RJ, Sousa-Pinto B, Bousquet J, Schünemann HJ, Zuberbier T, Bognanni A, Togias A, Samolinski B, Valiulis A, Williams S, Bedbrook A, Czarlewski W, Torres MJ, Shamji MH, Morais-Almeida M, Canonica GW, Vecillas LL, Dykewicz MS, Jacomelli C, Klimek L, Leemann L, Lourenço O, Papadopoulos NG, Pereira AM, Savouré M, Toppila-Salmi SK, Ventura MT, Yepes-Nuñez JJ, Cruz AA, Ciprandi G, Gemicioglu B, Giovannini M, Gradauskiene B, Jartti T, Jeseňák M, Kuna P, Kvedariene V, Larenas-Linnemann DE, Latiff AHA, Mohammad Y, Ohta K, Mahesh PA, Pali-Schöll I, Pfaar O, Regateiro FS, Roche N, Taborda-Barata L, Ulrik CS, Viegi G, Zhang L, Haahtela T, Cherrez-Ojeda I, Ivancevich JC, Khaltaev N, Yorgancioglu A, Abdullah B, Al-Ahmad M, Al-Nesf MA, Amaral R, Asllani J, Bergmann KC, Bernstein JA, Blaiss MS, Toskala E, Carreiro-Martins P, Casale T, Cecchi L, Fiocchi A, Giuliano AFM, Christoff G, Cirule I, de Sousa JC, Costa EM, Devillier P, Hossny E, Iinuma T, Ispayeva Z, Julge K, Kaidashev I, Bennoor KS, Kraxner H, Kull I, Kulus M, Kupczyk M, Kurchenko A, La Grutta S, Miculinic N, Tuyet LLT, Lee SM, Montefort S, Moreira A, Mullol J, Nadif R, Nakonechna A, Neffen HE, Niedoszytko M, O'Hehir RE, Ogulur I, Okamoto Y, Olze H, Palomares O, Panzner P, Patella V, Pitsios C, Puggioni F, Quirce S, Ramonaité A, Repka-Ramirez MS, Roberts G, Robles-Velasco K, Rottem M, Salapatas M, Sastre J, Scichilone N, Sisul JC, Solé D, Soto-Martinez ME, Sova M, Tantilipikorn P, Todo-Bom A, Tsaryk V, Tsiligianni I, Urrutia-Pereira M, Valovirta E, Vasankari T, Wallace D, Wang Y, Worm M, Yusuf OM, Gil-Mata S, Marques-Cruz M, Mahboub B, Romano A, Aberer W, Artesani MC, Azzolini E, Barreto B, Bartra J, Becker S, Beghe B, Boner A, Borowiack E, Bouchard J, Brussino L, Buhl R, Catamerò F, Charpin D, Chavannes NH, Chełmińska M, Cheng L, Chkhartishvili E, Cho SH, Chong-Neto HJ, Chu DK, Cingi C, Compalati E, Costa RA, Cvetkovski B, Cardona V, D'Amato G, Davies JM, Di Bona D, Gonzalez Diaz SN, Dimou MV, Doulaptsi M, Ferreira-da-Silva R, Gawlik R, Calvo-Gil M, Gómez MR, Gotua M, Grigoreas C, Guzman MA, House R, Hyland M, Ierodiakonou D, Karavelia A, Keith P, Kisiel M, Kosak TS, Kosnik M, Koyuncu IV, Kritikos V, Litynska J, Lombardi C, Louis G, Luo X, Martini M, Meço C, Mesonjesi E, Mihaltan F, Moniuszko M, Naclerio RN, Neisinger S, Ollert M, Ordak M, Paoletti G, Parmelli E, Perdomo-Flores EA, Pereira H, Pérez JMF, Pham-Thi N, Prokopakis E, Ribeiro-Vaz I, Rolla G, Romantowski J, Rombaux P, Rouadi PW, Ryan D, Sadowska E, Sakurai D, Salameh L, Serrano E, Da Silva J, Soyka MB, Specjalski K, Tomic-Spiric V, Stevanovic K, Subramaniam A, Thomander T, Tong W, Vachova M, van Hage M, Wagenmann M, Ko FWS, Werminghaus P, Xepapadaki PV, Xiang YK, Yang Q, Zhang H, Zuberbier J, Fonseca JA.   +230 more
europepmc   +2 more sources

Modulation of Bilastine Crystallinity for Enhanced Dissolution and Oral Bioavailability [PDF]

Pharmaceutical Sciences
Background: Bilastine is a second-generation antihistamine belonging to poorly soluble, highly permeable drug class. This resulted in low and variable oral bioavailability. Being antihistaminic, its combination with caffeine is possible. Accordingly, the
Zeinab M. Elrefaey, Rania K. Eid, Mona F. Arafa, Mohamed Nasr, Gamal M. El Maghraby   +4 more
doaj   +1 more source

Bilastin [PDF]

pharma-kritik, 2012
Ein neues Antihistaminikum, das bei allergischer Rhinitis und Urtikaria ähnlich wie andere sogen. nicht-sedierende Antihistaminika – z.B. Cetirizin – die Symptome lindert. Es unterscheidet sich nicht wesentlich von anderen Substanzen dieser Gruppe.
openaire   +1 more source

Bilastine: new insight into antihistamine treatment [PDF]

Clinical and Molecular Allergy, 2015
Bilastine is a new second generation H1-antihistamine recently approved for the symptomatic treatment of allergic rhinitis (AR) and chronic urticaria (CU). Bilastine epitomizes the evolution of research on antihistamines concerning both efficacy and safety.
RIDOLO, Erminia, Montagni, Marcello, Bonzano, Laura, Incorvaia, Cristoforo, Canonica, Giorgio Walter   +4 more
openaire   +4 more sources